COMP <GO>
TXG vs MRK // FREE CASH FLOW YIELD
10x Genomics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: TXG 4
— MRK 10
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $70.11 (-14.03%) • MKT CAP: $10.63B
fcf-yield
1.22%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 74.80% | -5.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 20.70% | -26.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.22% | 3.42% | -2.20 | MRK | /fcf-yield <GO> |
| Operating Margin | -9.50% | 34.30% | -43.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 28.10% | -34.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 1.30% | +3.90 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 5.19 | +19.83 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 56.9 | -12.37 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 18.4x | +5.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.63B | $361.02B | -$350.40B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | MRK REV | TXG GROSS % | MRK GROSS % | TXG FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $65.01B | 69.1% | 74.8% | $130.1M | $12.36B |
| FY 2024 | $610.8M | $64.17B | 67.9% | 76.3% | -$5.7M | $18.10B |
| FY 2023 | $618.7M | $60.12B | 44.0% | 44.0% | -$43.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
MRK // BETA 0.92